Mangafodipir as an Adjunct to Percutaneous Coronary Intervention
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The present feasibility study is designed to find out whether pre-treatment with the compound
mangafodipir (PP-099) provides an additional reduction in myocardial infarct size in patients
treated with primary percutaneous coronary intervention (PCI) during acute myocardial
infarction (AMI).